CMIC HOLDINGS Co., Ltd. completed the acquisition of Hamamatsu Pharma Research Inc. from Hiroyuki Takamatsu.
October 30, 2023
Share
CMIC HOLDINGS Co., Ltd. (TSE:2309) signed a contract to acquire Hamamatsu Pharma Research Inc. from Hiroyuki Takamatsu on October 26, 2023. The transaction is expected to complete on October 31, 2023.
CMIC HOLDINGS Co., Ltd. (TSE:2309) completed the acquisition of Hamamatsu Pharma Research Inc. from Hiroyuki Takamatsu on October 31, 2023.
CMIC HOLDINGS Co., Ltd. mainly provides pharmaceutical development support services. The Contract Research Organization (CRO) segment offers monitoring, data management, pharmaceutical consulting and nonclinical services. The Contract Manufacturing Organization (CMO) segment is engaged in the entrusted manufacture of drugs for pharmaceutical companies. The Contract Sales Organization (CSO) segment is engaged in the operation and marketing support for medicinal products. The Health Care segment conducts site support institute (SMO) business, and provides health care information services. The Intellectual Property Development (IPD) segment develops and sells diagnostic products and orphan drugs.